Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 7/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661856 | 0.84 | RAB9A (0.59) | HTTSMN1; SMN2 | |
| SCHEMBL23405932 | 0.74 | GRM5 (0.64) | MAPK1WNT3AGRM5SMN1; SMN2 | |
| SCHEMBL20641476 | 0.74 | RAB9A (0.66) | GRM5 | |
| SCHEMBL2574821 | 0.74 | CHEK1 (0.52) | MAPK1PIK3CAWNT3AHTT | |
| SCHEMBL10852703 | 0.72 | RAB9A (0.51) | HTTSMN1; SMN2 | |
| SCHEMBL10760410 | 0.72 | RAB9A (0.48) | HTTSMN1; SMN2 | |
| SCHEMBL23405893 | 0.71 | RAB9A (0.67) | GRM5 | |
| SCHEMBL5452138 | 0.71 | MAPK1 (0.82) | MAPK1PIK3CA | |
| SCHEMBL23406055 | 0.70 | SMN1; SMN2 (0.65) | GRM5SMN1; SMN2 | |
| SCHEMBL23406072 | 0.70 | DEGS1 (0.63) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4448780-A | N-(Lower-alkyl)-N'-[5-(pyridinyl)-2-pyridinyl]ureas and cardiotonic use thereof | STERLING DRUG INC. (US) | 1984-05-15 | — | — | US | disclosed |